GlobeNewsWire
06 May 2026, 20:05 UTC · 20w ago
Verdict
Headline leans bullish. We score BLLN +1.00 across five claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+1.00strongly bullish
What the story claims
5 claims · scored −1 bearish … +1 bullish
BillionToOne shifted from a net loss of $4.0 million to a net income of $18.0 million in Q1 2026.
So whatA swing to profitability is a major valuation catalyst for growth-stage diagnostics companies.
More positive than 99% of claims this week
The company raised its full-year 2026 total revenue guidance to $450.0 million - $465.0 million from the previous $430 million - $445 million.
Continue reading
5 related stories
More positive than 98% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 97% of claims this week
Q1 2026 total revenue grew 84% year-over-year to $108.4 million, driven by a 44% increase in tests and a 28% increase in average selling price (ASP).
So whatHigh double-digit growth combined with increasing pricing power suggests a strong competitive position.
More positive than 92% of claims this week
BillionToOne expanded its US payor contracts to reach $300 million in contracted lives.
More positive than 86% of claims this week
Gross margin improved to 73% in Q1 2026 from 64% in Q1 2025.
More positive than 77% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The company reported significant revenue growth, a shift to net profitability, and raised its full-year 2026 guidance.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
2h ago
+40.6%
Price agrees with the score
$114.42 vs $81.40 close before publication (May 6) · not market-adjusted
BLLN chart →
